Identifai Genetics (ASX:ID1) at a 52-Week High: What’s Next for Investors?

Sonal Goyal

21 October 2026 10:51 PM AEDT

Identifai Genetics (ASX:ID1) at a 52-Week High: What’s Next for Investors?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key highlights

ID1 touched a 52-week high on 21 October 2026 and closed at $0.50, up 1.01% for the day.
The company listed on 13 October 2026 after raising A$10 million at A$0.20 per share.
Proceeds support US laboratory readiness and clinical validation for the Windrose prenatal screening platform.

On 21 October 2026, Identifai Genetics Ltd (ASX:ID1) hit a 52-week high during the trading session. Shares closed the day at $0.50, up 1.01%. Identifai Genetics is a prenatal genetic screening company that listed on the ASX in October 2026.

What Identifai Genetics does

Identifai Genetics Limited is developing Windrose, a prenatal screening platform that combines genomic sequencing, AI and Machine Learning to assess selected inherited conditions from a single maternal blood sample from about nine weeks of pregnancy. The technology originated at Tel Aviv University and is supported by 11 Patent families.

ASX listing and IPO

In an announcement dated 13 October 2026, Identifai said it had begun trading on the ASX under code ID1 after an IPO raising A$10 million at A$0.20 per share. The United States is the first target commercial market, and proceeds will support US laboratory readiness, assay validation, a planned multicentre clinical validation study and further product development. The company noted that its priorities are laboratory readiness, the clinical validation program and staged product releases while pursuing commercial partnerships.

Sector context

Very small listed companies often have low trading volumes, which means share prices can move by large percentages on small trades.

Risks and uncertainties

The stock has only recently listed, so a 52-week high covers a very short trading history and the closing price is well above the A$0.20 IPO price. Windrose is not yet commercial, and clinical validation, regulatory and laboratory milestones must be met. Closing prices on a single day are not the same as the 52-week high or low price, and a 52-week extreme does not indicate where a share price will move next.

Catalysts to watch

Items to watch include the clinical validation study, US laboratory readiness, commercial partnerships and staged product releases.

Closing perspective

Identifai’s 13 October 2026 listing announcement set out its Windrose strategy and use of proceeds. Later updates will report validation progress.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.